Abstract:Aim: To assess platelet (PLT) function and bleeding risks in patients with acute coronary syndrome after tirofiban infusion.Methods: Patients diagnosed with acute coronary syndrome from May 2016 to February 2018 in the Department of Cardiac Intensive Care Unit, Zhongshan Hospital, were enrolled. They were symmetrically allocated into two groups: tirofiban treatment group or control group (without tirofiban treatment). Blood samples were collected 24 h postoperation for the evaluation of antiplatelet effect of tirofiban. We applied thromboelastography to detect on-treatment PLT reactivity and conducted laboratory tests to assess the risk of bleeding following tirofiban treatment. After discharge, telephone follow-up and outpatient interview were carried out. The primary clinical endpoint was major adverse cardiovascular events, including cardiovascular death, cardiovascular mortality, myocardial infarction, and revascularization for the targeted vascular lesion.Results: There were a total of 196 patients with acute coronary syndrome after screening with the inclusion criteria and the exclusion criteria. Ninety-eight patients were assigned to receive either tirofiban treatment or control treatment. Patients treated with tirofiban had more coronary lesions and stents implanted compared with the control group (P = 0.000). After tirofiban infusion, inhibition of platelet aggregation induced by thromboxane A2 and adenosine diphosphate was significantly higher compared to patients without tirofiban infusion (80.3% ± 19.6% vs. 72.6% ± 13.0%, P = 0.002; and 81.0% ± 19.8% vs. 75.4% ± 12.4%, P = 0.020, respectively). There was no significant difference in the reduction of hemoglobin (Hb), hematocrit (Hct), and PLT after administration of tirofiban, compared with baseline (P > 0.05). In addition, no significant differences were identified between the two groups with respect to Hb, Hct, and PLT after tirofiban infusion. However, C-reactive protein level, referred to as an inflammation marker, was significantly lowered after infusion tirofiban compared with the control group (11.9 ± 14.2 vs. 17.9 ± 21.2, P = 0.020). During the 1-year follow-up, the incidence rate of major adverse cardiovascular events remains indiscriminate between the two groups (P = 0.208). The assessments of cardiac biomarkers showed that tirofiban could decrease incidence of procedural myocardial infarction (odds ratio [OR] = 0.250, 95% confidence interval [CI] = 0.067–0.925, P = 0.027). At follow-up, the morbidity of left atrial dilation in tirofiban-treated patients, defined as enlargement of left atrial diameter >40mm, was lower compared to the control group (OR = 0.533, 95% CI = 0.301–0.945, P = 0.031).Conclusion: Tirofiban infusion could decrease PLT activation in patients with acute coronary syndrome without increasing the risk of bleeding. As a concomitant medication, tirofiban shows no benefit in reducing the occurrence of major adverse cardiovascular events.

Effect of Pretreatment with Aspirin and Ticlopidine on the Change of Platelet Aggregability after Radiofrequency Catheter Ablation

EFFECT OF HEPARIN ON ACTIVATION OF PLATELET FUNCTION IN PATIENTS DURING RADIOFREQUENCY CATHETER ABLATION

Effect of Radiofrequency Ablation on Endothelial Function and Platelet Activation

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Effects of Diltiazem on Platelet Activation and Cytosolic Calcium During Percutaneous Transluminal Coronary Angioplasty.

Effect of remote ischemic preconditioning on left atrial remodeling and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation.

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Evaluation of the efficacy of anti-platelet aggregation drugs in patients using thromboelastograph after percutaneous transluminal angioplasty and stenting

Effect of Ticagrelor Versus Clopidogrel After Off-Pump Coronary Artery Bypass Grafting on Postoperative Atrial Fibrillation: A Cohort Study

Clinical Efficacy of Ticagrelor in Patients Undergoing Emergency Intervention for Acute Myocardial Infarction and Its Impact on Platelet Aggregation Rate

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion

The relationships between anticoagulation therapy during operation and thromboembolic events in pa-tients with persistent/permanent atrial fibrillation who underwent radiofrequency catheter ablation

Effect of Antiplatelet Pretreatment on Platelet Aggregation and Clinical Outcomes in Acute Ischemic Stroke Patients Treated with Recombinant Tissue-Type Plasminogen Activator.

Short and Long-Term Changes in Platelet and Inflammatory Biomarkers after Cryoballoon and Radiofrequency Ablation.

Evaluating the effect of different doses of aspirin on the platelet inhibition rate by thromboelastography

Ticagrelor Enhances Adenosine-Mediated Antiplatelet Effect In Acute Coronary Syndrome Patients-A Prospective Cohort Study

Effect of tirofiban on flow in patients with acute coronary syndrom during primary PCI

Effects of Different Antithrombotic Interventions on Platelet Activation in Patients with Atrial Fibrillation

Effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with non-ST-elevation myocardial infarction

Safety and Efficacy of Dabigatran for the Peri-Procedural Anticoagulation in Patients Undergoing Abla-Tion of Atrial Tachyarrhythmias

Influences of tirofiban hydrochloride on platelet aggregation rate,sCD40L level and prognosis in patients with non-ST-elevation acute coronary syndrome